Skip to main content
  1. Right Decisions
  2. Scottish Palliative Care Guidelines
  3. Pain
  4. Back
  5. Pain medicines / analgesics
  6. Methadone
Important: please update your RDS app to version 4.7.3 Details with newsletter below.

Please update your RDS app to v4.7.3

We asked you in January to update to v4.7.2.  After the deployment planned for 27th February, this new update will be needed to ensure that you are able to download RDS toolkits even when the RDS website is not available. We will wait until as many users as possible have downloaded the new version before switching off the old system for app downloads and moving entirely to the new approach.

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. 

To update to the latest release:

 On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Right Decision Service newsletter: February 2025

Welcome to the February 2025 update from the RDS team

1.     Next release of RDS

 

A new release of RDS is planned (subject to outcomes of current testing) for week beginning 24th February. This will deliver:

 

  • Fixes to mitigate the recurring glitches with the RDS admin area and the occasional brief user interface outages which have arisen following implementation of the new distributed technology infrastructure in December 2024.

 

  • Capability to embed content from Google calendar, Google Maps, Daily Motion, Twitter feeds, Microsoft Stream into RDS pages.

 

  • Capability to include simple multiplication in RDS calculators.

 

The release will also incorporate a number of small fixes, including:

  • Exporting of form within Medicines Sick Day Guidance in polypharmacy toolkit
  • Links to redundant content appearing in search in some RDS toolkits
  • Inclusion of accordion headers alongside accordion text in search result snippets.
  • Feedback form on mobile app.
  • Internal links on mobile app version of benzo tapering tool

 

We will let you know when the date and time for the new release are confirmed.

 

2.     New RDS developments

There is now the capability to publish toolkits on the web with left hand side navigation rather than tiles on the homepage. To use this feature, turn on the “Toggle navigation panel” option at the top of the Page settings menu at toolkit homepage level – see below. Please note that publication to downloadable mobile app for this type of navigation is still under development.

The Benzodiazepine tapering tool (https://rightdecisions.scot.nhs.uk/benzotapering) is now available as part of the RDS toolkit for the national benzodiazepine prescribing guidance developed by the Scottish Government Effective Prescribing team. The tool uses this national guidance developed with a wide-ranging multidisciplinary group. This should be used in combination with professional judgement and an understanding of the needs of the individual patient.

3.     Archiving and version control and new RDS Search and Browse interface

Due to the intensive work Tactuum has had to undertake on the new technology infrastructure has pushed back the delivery dates again and some new requirements have come out of the recent user acceptance testing. It now looks likely to be an April release for the search and browse interface. The archiving and version control functionality may be released earlier. We’ll keep you posted.

4.     Statistics

At the end of January, Olivia completed the generation of the latest set of usage statistics for all RDS toolkits. If you would like a copy of the stats for your toolkit, please contact Olivia.graham@nhs.scot .

 

5.     Review of content past its review date

We have now generated reports of all RDS toolkit content that has exceeded its review date by 6 months or more. We will be in touch later this month with toolkit owners and editors to agree the plan for updating or withdrawing out of date content.

 

6.     Toolkits in development

Some important toolkits in development by the RDS team include:

  • National CVD prevention pathways – due for release end of March 2025.
  • National respiratory pathways, optimal cancer diagnostic pathways and cancer prehabilitation pathways from the Centre for Sustainable Delivery. We will shortly start work on the national cancer referral pathways, first version due for release via RDS around end of June 2025.
  • HIS Quality of Care Review toolkit – currently in final stages of quality assurance.

 

The RDS team and other information scientists in HIS have also been producing evidence summaries for the Scottish Government Realistic Medicine team, to inform development of national guidance around Procedures of Limited Clinical Value. This guidance will in due course be translated into an RDS toolkit.

 

7. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Friday 28th February 12-1 pm
  • Tuesday 11th March 4-5 pm

 

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

 

To invite colleagues to sign up to receive this newsletter, please signpost them to the registration form  - also available in End-user and Provider sections of the RDS Learning and Support area.   If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

 

Methadone

Red – For medicines normally initiated and used under specialist guidance

Introduction

The information below is intended as a guide for use in primary and secondary care to support the management of patients receiving methadone as a third-line analgesic for complex pain. 

Methadone should only be started by a consultant in palliative medicine and patients require ongoing specialist supervision.  

 

Description

Methadone is a potent, synthetic opioid. Methadone has complex pharmacokinetics and a long half-life. There is a risk of accumulation, especially in elderly patients.

Preparations

Tables are best viewed in landscape mode on mobile devices

Oral Methadone tablets

Methadone liquid
5mg (preferred form)

1mg/ml (green)

10mg/ml (blue)
Injection Methadone injection 10mg/ml (1ml, 2ml, 3.5ml, 5ml ampoules)

 

Indications

Methadone is only used as a third-line opioid for patients with complex pain that is poorly responsive to other opioids, or where these opioids have resulted in intolerable side effects.

  • Patient has responded poorly or had intolerable side effects from first and second-line opioids (for example morphine, diamorphine, oxycodone, fentanyl).
  • In complex neuropathic pain: if the patient has not responded to first and second-line opioid and adjuvant analgesic combinations.
  • In end-stage chronic kidney disease (eGFR less than 30ml/min).

Adjuvant methadone may also be used for the above indications under specialist supervision.

 

Cautions

Methadone should always be used with caution but particularly in the following situations.

  • Methadone has a long and unpredictable half-life which can lead to side effects/severe opioid toxicity without a change in the regular dose, particularly when methadone is started for the first time – careful monitoring is needed.
  • Patients with incident pain or unstable pain where repeated doses of methadone may accumulate and cause opioid toxicity.
  • Pain suspected to have a strong psychological component as repeated demands for as needed doses of methadone may lead to opioid toxicity.

 

Drug interactions:

  • Hepatic methadone metabolism varies considerably between individuals and this variability is responsible for the large differences in methadone clearance and the doses needed to manage pain. 
  • QTMethadone levels may increase if given with fluoxetine, sertraline, clarithromycin, ciprofloxacin, fluconazole. Methadone should not be given with monoamine oxidase inhibitors (for example phenelzine and linezolid) or within 2 weeks of stopping them.
  • Methadone levels may decrease if given with phenytoin, phenobarbital, carbamazepine, St John’s Wort.
  • Concurrent administration with medications that affect methadone metabolism via the hepatic cytochrome P450 system (CYP3A4) – refer to British National Formulary (BNF). Methadone can cause QT prolongation – caution with other drugs that may have this effect, for example QTclarithromycin, amitriptyline, QTcitalopram, QTdomperidone, prochlorperazine, QThaloperidol, QTamiodarone. Refer to BNF.

 

Liver impairment: Reduced clearance. Dose reduction may be necessary.

Renal impairment: No dose reduction necessary. Not significantly removed by dialysis.

 

Side effects

  • Patient may become unexpectedly drowsy or develop respiratory depression particularly when first starting methadone – refer to cautions above.
  • Side effects that are common to all opioids, including dry mouth, constipation may be less common.

 

Dose and administration

  • Patients starting methadone will usually require inpatient admission for 5 to 7 days. A stable methadone dose for 48 to 72 hours before discharge is needed.  
  • Methadone may occasionally be started safely as an adjuvant analgesic for selected patients in the community. The palliative care specialist will recommend an individual dosing regimen and discuss and review the management plan with the patient’s GP.
  • Methadone is usually given twice daily (occasionally three times daily). 
  • A shorter acting opioid than methadone is often used for breakthrough pain in patients on a stable methadone dose. 
  • The methadone dose and the timing of doses should not be changed without instructions from a palliative medicine specialist.

 

Discontinuing methadone: Seek specialist advice.

This may be needed if treatment is ineffective, the patient is experiencing side effects, is unable to take oral medication or is in the last days of life.

 

Practice points

  • Undertake an individual risk assessment prior to initiating methadone. Consider if drug diversion/misuse is likely and if weekly/twice weekly dispensing from a community pharmacy is required.
  • Discuss the methadone prescription with the GP and provide written information.
  • Ensure the GP is aware which methadone preparation should be prescribed if the patient is receiving methadone liquid.
  • Ensure the patient is reviewed by a member of the specialist palliative care team as soon as possible after discharge (within 2 to 3 days).
  • Discuss the prescription with community pharmacy and explain methadone has been prescribed for pain management not drug dependency.

 

References

Blackburn D. Methadone: the analgesic. European Journal of Palliative Care 2005;12:188-191.

Nicholson AB. Methadone for cancer pain. Cochrane database of systematic reviews 2008;(4). http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003971.pub3/pdf/standard

Prommer EE. Methadone for cancer pain. Palliative Care: Research & treatment 2010; 4(1-10).

Twycross R et al. Palliative Care Formulary (4th Ed). Palliativedrugs.com Ltd, Nottingham, 2011.

Acknowledgement: Brown DJF. Methadone for cancer pain: A reference for specialists. St Columba’s Hospice, Edinburgh, 2007.